Phase 3 Trial Initiated for New Diabetic Macular Edema Drug
Researchers have begun a late-stage study of a single-injection therapy designed to reduce the frequent treatment burden for people with DME.
Updated on Sept. 28, 2026 in Diabetes
Live Poll
Do you trust that new medical therapies can successfully replace frequent injection schedules for chronic diseases?
4D Molecular Therapeutics has launched the 4SIGHT Phase 3 clinical trial to evaluate 4D-150, a potential gene therapy treatment for diabetic macular edema (DME). This global, multicenter study involves 514 participants and aims to offer a long-term alternative to the current standard of frequent anti-VEGF eye injections.
Why it matters
Managing diabetic macular edema often requires an exhausting schedule of recurring injections to prevent vision loss, leading to poor adherence for many patients. If successful, this new therapy could provide sustained disease control through a single treatment, potentially transforming how clinicians manage this common diabetes complication.
The 4SIGHT Phase 3 trial is a multicenter, randomized, double-masked study enrolling 514 patients to compare the efficacy of 4D-150 against a 2 mg aflibercept control group. While previous data from the SPECTRA clinical trial reached a cutoff in March 2026, the current phase remains ongoing.
The players
4D Molecular Therapeutics
An Emeryville-based biotechnology company developing gene therapies for retinal and genetic diseases.
The details
4D-150 is designed to provide sustained control of retinal diseases through a single intravitreal injection. Unlike current anti-VEGF therapies that require consistent, repeated injections, this treatment aims to serve as a continuous backbone therapy. In the 4SIGHT trial, participants undergo a run-in period receiving five aflibercept loading doses before receiving the experimental therapy, with success measured at the 52-week mark.
Timeline
March 12, 2026: Data cutoff date for the SPECTRA clinical trial.
September 28, 2026: 4D Molecular Therapeutics initiated the 4SIGHT clinical trial.
Week 52: Primary endpoint assessment scheduled for the 4SIGHT trial.
Health Landscape
The development of 4D-150 represents a shift in the treatment landscape for diabetic macular edema, moving from repetitive anti-VEGF management toward sustained gene therapy. This approach follows the established framework of the FDA Regenerative Medicine Advanced Therapy designation program to expedite innovative treatments.
If you are managing diabetic macular edema, these clinical trial developments represent potential future shifts in treatment frequency and long-term care. It is worth discussing with your ophthalmologist how evolving gene therapy research might impact your future management options as new data emerges.
The takeaway
The move toward single-injection therapies for diabetic macular edema addresses the significant treatment burden currently faced by patients. Patients should continue their prescribed anti-VEGF schedules and consult their retina specialist about the latest clinical trial advancements for sustained disease control.
Further reading
For more on managing diabetic eye complications, visit our Diabetes section.
Live Poll
Do you trust that new medical therapies can successfully replace frequent injection schedules for chronic diseases?
